AR123110A1 - Vacunas anticoronavirus - Google Patents
Vacunas anticoronavirusInfo
- Publication number
- AR123110A1 AR123110A1 ARP210102144A ARP210102144A AR123110A1 AR 123110 A1 AR123110 A1 AR 123110A1 AR P210102144 A ARP210102144 A AR P210102144A AR P210102144 A ARP210102144 A AR P210102144A AR 123110 A1 AR123110 A1 AR 123110A1
- Authority
- AR
- Argentina
- Prior art keywords
- coronavirus
- spike protein
- composition
- immunogenic fragment
- adjuvant
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54366—Apparatus specially adapted for solid-phase testing
- G01N33/54386—Analytical elements
- G01N33/54387—Immunochromatographic test strips
- G01N33/54388—Immunochromatographic test strips based on lateral flow
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56983—Viruses
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
- G01N2333/08—RNA viruses
- G01N2333/165—Coronaviridae, e.g. avian infectious bronchitis virus
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2469/00—Immunoassays for the detection of microorganisms
- G01N2469/20—Detection of antibodies in sample from host which are directed against antigens from microorganisms
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Virology (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Analytical Chemistry (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- General Physics & Mathematics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Reivindicación 1: Una composición caracterizada porque comprende a coronavirus, una proteína espicular de dicho coronavirus o un fragmento inmunogénico de dicha proteína espicular, y un adyuvante que comprende una saponina, un esterol, y un oligonucleótido inmunoestimulador que contiene CpG. Reivindicación 6: Una composición que comprende un coronavirus, una proteína espicular de dicho coronavirus o un fragmento inmunogénico de dicha proteína espicular, y un adyuvante caracterizada porque comprende un oligonucleótido inmunoestimulador que contiene CpG y un glicolípido de acuerdo con la fórmula (1), en donde, R¹ es hidrógeno, o un radical alquilo saturado que tiene hasta 20 átomos de carbono; X es -CH₂-, -O- o -NH-; R² es hidrógeno, o un radical alquilo saturado o insaturado que tiene hasta 20 átomos de carbono; R³, R⁴, y R⁵ son independientemente hidrógeno, -SO₄²⁻, -PO₄²⁻, -COC₁₋₁₀ alquilo; R⁶ es L-alanilo, L-a-aminobutilo, L-arginilo, L-asparginilo, L-aspartilo, L-cisteinilo, L-glutamilo, L-glicilo, L-histidilo, L-hidroxiprolilo, L-isoleucilo, L-leucilo, L-lisilo, L-metionilo, L-ornitinilo, L-fenialani, L-prolilo, L-serilo, L-treonilo, L-tirosilo, L-triptofanilo y L-valilo o sus D-isómeros. Reivindicación 17: Una composición que comprende un coronavirus, una proteína espicular de dicho coronavirus o un fragmento inmunogénico de dicha proteína espicular, y un adyuvante caracterizada porque comprende una saponina, a esterol, un compuesto de amonio cuaternario, y un polímero de ácido poliacrílico.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063064225P | 2020-08-11 | 2020-08-11 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR123110A1 true AR123110A1 (es) | 2022-10-26 |
Family
ID=77499919
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP210102144A AR123110A1 (es) | 2020-08-11 | 2021-07-30 | Vacunas anticoronavirus |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20220050102A1 (es) |
| EP (1) | EP4196787A1 (es) |
| AR (1) | AR123110A1 (es) |
| WO (1) | WO2022035611A1 (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024133928A1 (en) * | 2022-12-23 | 2024-06-27 | Pericard Check Gmbh | Lateral flow device for the detection of acute aortic syndrome |
| EP4390396A1 (en) * | 2022-12-23 | 2024-06-26 | PeriCard Check GmbH | Lateral flow device for the detection of acute aortic syndrome |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10960070B2 (en) | 2016-10-25 | 2021-03-30 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Prefusion coronavirus spike proteins and their use |
-
2021
- 2021-07-30 AR ARP210102144A patent/AR123110A1/es unknown
- 2021-07-30 EP EP21759457.1A patent/EP4196787A1/en active Pending
- 2021-07-30 WO PCT/US2021/043821 patent/WO2022035611A1/en unknown
- 2021-07-30 US US17/389,473 patent/US20220050102A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20220050102A1 (en) | 2022-02-17 |
| WO2022035611A1 (en) | 2022-02-17 |
| EP4196787A1 (en) | 2023-06-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR123110A1 (es) | Vacunas anticoronavirus | |
| JP2022121437A5 (es) | ||
| RU2016109925A (ru) | Адъюванты на масляной основе | |
| AR059192A1 (es) | Composiciones coadyuvantes glicolipidicas | |
| MX2020001734A (es) | Derivados de 6-amino-7,9-dihidro-8h-purina-8-ona como agonistas inmunoestimulantes del receptor 7 tipo toll (tlr7). | |
| CN101874112B (zh) | 特别是作为免疫刺激剂/佐剂的式(I)：GlXmGn或式(II)：ClXmCn的核酸 | |
| ES2296390T3 (es) | Composicion coadyuvante y procedimiento para su uso. | |
| ES2235330T3 (es) | Analogos de saponionas triterpenicas que tienen actividad ayuvante. | |
| TWI301067B (en) | Microfluidized oil-in-water emulsions and vaccine compositions | |
| MX2020001475A (es) | Derivados de 6-amino-7,9-dihidro-8h-purin-8-ona como agonistas del receptor 7 tipo toll (tlr7) inmunoestimulantes. | |
| ES2315880T3 (es) | Composiciones y procedimientos para estabilizar formulaciones adyuvantes con base lipidica usando glucolipidos. | |
| CN111212846B (zh) | 三萜皂苷类似物 | |
| CA2768195A1 (en) | Lipidated oxoadenine derivatives | |
| RU2001108569A (ru) | Стабилизированная фармацевтическая композиция в лиофилизированной форме | |
| ES2227698T3 (es) | Formulacion de lipidos inmunoestimuladores. | |
| US20230100089A1 (en) | Methods and composition for induction of immune response | |
| BR0212556A (pt) | interleucina-12 como um adjuvante de vacina veterinária | |
| CA2367033A1 (en) | Fabric softening compositions comprising antioxidants for malodour reduction | |
| BRPI0818718B1 (pt) | processo de preparo de uma composição de vacina compreendendo antígeno e adjuvante na forma de látex inverso de homopolímero do ácido acrílico | |
| EP3676250A1 (en) | Peptide conjugates, conjugation process, and uses thereof | |
| CZ99796A3 (en) | The use of muramyl peptide compound | |
| ES2894138T3 (es) | Composiciones de vacuna novedosas que comprenden oligonucleótidos inmunoestimulantes | |
| HRP20210872T1 (hr) | Liposomni adjuvantni pripravci | |
| WO2019122050A1 (en) | Methods of immunization | |
| EP3007725A1 (en) | Beta-glycolipids for use as adjuvants |